(Boston, MA): The Neuroendocrine Tumor Research Foundation (NETRF) is proud to join Chimeric Therapeutics in announcing that CAR T-cell therapy using CHM CDH17 has been
Pancreatic neuroendocrine tumors (PanNETs) can have a variety of behaviors. Some stay slow-growing for years, while others take a sudden, aggressive turn, even when they’re
In a breakthrough for those with advanced pheochromocytoma and paraganglioma (Pheo/Para), the U.S. Food and Drug Administration (FDA) has approved WELIREG® (belzutifan) as a treatment
In a recent interview with CancerNetwork®, Dr. Anna Greene, Director of Research at the Neuroendocrine Tumor Research Foundation (NETRF), spotlighted the foundation’s leadership as the
Patient enrollment has begun at a fourth site for the world’s first CAR T-cell therapy clinical trial for neuroendocrine cancer. Winship Cancer Center at Emory
Lung neuroendocrine tumors (lung NETs) make up 20-30% of all neuroendocrine cancers, yet their diversity and complexity have long puzzled researchers and clinicians. Now, thanks
A new global clinical trial is evaluating the investigational drug FORE8394 (plixorafenib) for treatment of neuroendocrine carcinomas with BRAF V600E-mutations. The phase 2 study aims
A new clinical trial at the University of Chicago Medicine is evaluating the combination of 177Lu-DOTATATE with fulvestrant in patients with advanced pancreatic neuroendocrine tumors
Neuroendocrine tumors (NETs) are complex cancers that can originate in various organs, including the ovaries. While primary ovarian NETs (PON) are uncommon, distinguishing them from
As the Director of Research at the Neuroendocrine Tumor Research Foundation (NETRF), I’ve dedicated my career to advancing science that gives patients and families more
